z-logo
Premium
Immune functions in inflammatory bowel and coeliac diseases
Author(s) -
Soppi E.,
Eskola J.,
Lehtonen O.P.,
Leino R.
Publication year - 1988
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1699-0463.1988.tb00953.x
Subject(s) - ulcerative colitis , enteropathy , immune system , immunology , lymphocyte , inflammatory bowel disease , secretion , penicillamine , medicine , disease , biology
Different immune functions of 10 patients with glutein‐sensitive enteropathy (GSE), 9 with Crohn's disease (CD), 11 with ulcerative colitis (UC) and 13 healthy controls were characterized. The numbers of suppressor T cells in GSE were comparable to those of the controls; otherwise, the lymphocyte subpopulations were decreased in these bowel diseases. In the whole‐blood cultures, the lymphocyte proliferative responses to PHA were normal in the bowel diseases, but the responses to Con A were decreased in CD. In cultures with D‐penicillamine, the inhibition of the helper effect of CD patients was more pronounced in PHA‐stimulated cultures than in Con A‐stimulated cultures. The total Ig and IgA production did not markedly differ among the groups. PWM‐induced IgM secretion was significantly decreased in GSE, CD and UC, and IgG secretion in CD and UC, as compared to controls. In GSE, an increased Con A inducible suppressor cell activity was observed in the IgM production. Altogether, no clear‐cut immunological imbalance was detected in any of the bowel diseases; this in agreement with previous works. However, there are some differences in the regulatory cell balance among the patients with GSE, CD and UC. The determination of lymphocyte proliferative responses to PHA and Con A together with D‐penicillamine seems to provide a new immunological criterium for distinguishing between Chrohn's disease and ulcerative colitis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here